CN1781933B - Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative - Google Patents

Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative Download PDF

Info

Publication number
CN1781933B
CN1781933B CN2004100964592A CN200410096459A CN1781933B CN 1781933 B CN1781933 B CN 1781933B CN 2004100964592 A CN2004100964592 A CN 2004100964592A CN 200410096459 A CN200410096459 A CN 200410096459A CN 1781933 B CN1781933 B CN 1781933B
Authority
CN
China
Prior art keywords
peg
ring
cys
conh
sch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004100964592A
Other languages
Chinese (zh)
Other versions
CN1781933A (en
Inventor
刘克良
蒋志龙
王良友
梁远军
许笑宇
吴萍
韩寒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CN2004100964592A priority Critical patent/CN1781933B/en
Priority to CN201110034234.4A priority patent/CN102174084B/en
Publication of CN1781933A publication Critical patent/CN1781933A/en
Application granted granted Critical
Publication of CN1781933B publication Critical patent/CN1781933B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a kind of cyclopeptide derivative containing natural or artificial amino acid substituted active thymosin alpha-1 segment, and the preparation process thereof, medicine composition and their medicines for treating or preventing diseases related to immune deficiency, hypoimmunity, etc.

Description

Thymosin active fragments cyclic peptide analogue and polyethylene glycol derivative thereof
Invention field
The present invention relates to thymosin active fragments and cyclic peptide analogue natural or that alpha-non-natural amino acid replaces, and polyethylene glycol derivative, and preparation method thereof, contain their pharmaceutical composition and the purposes in the middle of diseases related such as treatment or prevention and immune deficiency, immunologic hypofunction thereof.
Background technology
Thymosin (T α 1) is a kind of important polypeptide para-immunity regulatory factor, effect with significant raise immunity is a kind of at the lymphocytic immunostimulant of T, can promote the ripe and differentiation of T cell, and impel the multiple lymphokine of sophisticated lymphocytic emiocytosis (as interleukin-2 and gamma-interferon etc.) can also promote the generation of interleukin-2 acceptor.T α 1 is made up of 28 amino-acid residues; molecular weight 3108; iso-electric point 4.2; the N-end is the acetylize structure, and its aminoacid sequence is as follows: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-L ys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-A sp-OH
In recent years, the research of T α 1 mainly concentrates on clinical application, and is few about the research report of its structure activity relationship.1980, synthetic T α such as Wong 1With desAc-T α 1, suppress the E-RFT by external azathioprine and show their activity and natural T α 1Quite, T α is described 1The acetylize of N-end whether it is not actively had an influence.Remove report T α such as Frasca 1N-end fragment 1-14 can in adult rat (the 6-18 month) body, promote the IL-2 expression of receptor, strengthen outside the activity of helper T cell, other studies show that T α 1The essentially no activity of N-end fragment, C-end parts fragment has preferably active.Abiko etc. confirm T α with external E-RFT 1Some C-end fragment have the part activity: T α 1 (100%), 14-28 (9.83%), 19-28 (1.04%).Felix etc. confirm N-end fragment 1-4,4-10,1-10 and the basic non-activity of 1-14 with intravital immunosuppressed mice test; C-end fragment 15-28 and 18-28 and T α 1Quite active; 21-28 (75%), 23-28 (50%) and 25-28 (50%) have the part activity.Ciaredelli etc. confirm T α with external mixed lymphocytes proliferation test (MLC) 1C-end 20-26,25-27 and 25-28 have about 90% activity.Report C-end fragment 13-19 such as Ho and T α 1In external activity with identical short Cord blood T lymphocyte differentiation and maturation, 20-25 and 20-28 have the part activity.The external sulphur azoles purine of usefulness such as Ciaredelli suppresses the E-RFT and finds that C-end 17-28 area part fragment has active preferably.
Grottesi etc. by circular dichroism spectrum (CD) and 2D-NMR to T α 1Conformation in solution is studied, and the result shows: T α 1In the aqueous solution, do not form the secondary conformation of advantage, but in hydrophobic environment, can form certain secondary structure.In trifluoroethanol 40% (TFE) aqueous solution, Val 5And Glu 8Between form β-corner, Lys 17And Glu 24Between form alpha-helix.Because T α 1Receptor structure is also still undiscovered, and Grottesi etc. infer T α 1With lymphocytic mechanism of action may be: T α 1At first form electrostatic interaction, induce Lys then by polare Aminosaeren residue and cytolemma 17To Glu 24Between sequence form α-Luo Xuanjiegou and embed cytolemma, and then stride the film district with the IL-2 acceptor electrostatic interaction take place.This action model helps to explain T α 1With the synergy of IL-2 in biological activity.
Type B viral hepatitis and hepatitis C can cause liver cirrhosis to cause liver cancer, and the whole world has 3.5 hundred million hepatitis b virus carriers and 1.5 hundred million hepatitis C carrier at present.China is hepatitis B big country, and the hepatitis B carriers more than 1.2 hundred million is arranged, and the hepatitis B patient more than 30,000,000 is arranged, the T α of chemosynthesis 1(Zadaxin) in 1996 at first in China listing, use separately or unite and use the treatment chronic hepatitis B with alpha-interferon.Zadaxin is equal to or is better than existing ethical goods in the curative effect aspect the treatment hepatitis B.Zadaxin all has certain curative effect for many other diseases (as hepatitis C, nonsmall-cell lung cancer, melanoma and acquired immune deficiency syndrome (AIDS) etc.).In addition, Zadaxin also can be used as the vaccine adjuvant, strengthens the immune effect of influenza vaccines and hepatitis B vaccine.At present, Zadaxin is just treated 3 clinical trial phases of HCV and 2 clinical trial phases of treatment liver cancer in the U.S., and 3 clinical trial phases of treatment HBV Japan carry out, and 2 clinical trial phases of treatment malignant melanoma carry out in Europe.This shows, research T α 1 and analogue thereof, seeking more efficiently, immunostimulant and antiviral drug have good prospect.
The present clinical T α 1 (Zadaxin) that uses is synthetic, costs an arm and a leg, dosage is big, the cycle is long, and therefore carrying out structure activity study finds that better analogue has application promise in clinical practice.Shortcomings such as the same with other peptide medicament, that T α 1 has is short such as the transformation period, easily be degraded in vivo, therefore T α 1 analogue of degraded has crucial meaning in active high, the antibody of design.
Summary of the invention:
The inventor and place laboratory study thereof have now found that T α 1 and derivative thereof have the biological activity of good preventing or treatment immune deficiency, immunologic hypofunction diseases related, the derivative that they and polyoxyethylene glycol form can keep the active while, prolonged the metabolic in vivo transformation period of compound of following (I), (IV), (VII), (VIII) group, thus reduced following (I), (IV), (VII), (VIII) group compound consumption and prolonged its action time in vivo.
Concrete, the present invention relates to T α as follows 1 active fragments derivative and steric isomer thereof.
One aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, and it is the compound of (I) group:
X 1-Y 1-Y 2-X 2
X 1-X 2-Y 1-Y 2-X 3
X 1-X 2-X 3-Y 1-Y 2-X 4
X 1-X 2-Y 1-Y 2-X 3-X 4
X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7 (I)
Wherein, X 1, X 2, X 3, X 4, X 5, X 6, X 7Be natural or non-natural alkalescence, acidity or the aromatic amino acid and the derivative thereof of L-or D-type independently, described basic aminoacids is selected from Arg, Lys, Glu, Cys, His, Trp, Mob, Nal, Pya, Phe (X) and Phg (X), wherein X is optional single the replacement or two replacements of hydrogen, halogen, nitro, carboxyl or C1-C4 alkyl, and substituting group is selected from H, 4-F, 3-F, 2-F, 4-Cl, 2-Cl, 4-Br, 2-Br, 3-Br, 2,5-2Cl, 4-F, 3-Cl, 3-NO 2Acidic amino acid is selected from: Asp, Glu, His, Tyr, Trp, Mob, Nal, Pya and Phg (X), wherein X is optional single the replacement or two replacements of hydrogen, halogen, nitro, carboxyl or C1-C4 alkyl, and substituting group is selected from H, 4-F, 3-F, 2-F, 4-Cl, 2-Cl, 4-Br, 2-Br, 3-Br, 2,5-2Cl, 4-F, 3-Cl, 3-NO 2
Y 1, Y 2, Y 3, Y 4Independently be that the natural or non-natural of L-or D-type is neutral, lipotropy or aromatic amino acid and derivative thereof, be selected from Gly, Ala, β-Ala, GABA, Val, Leu, Ile, Pro, His, Tyr, Trp, Mob, Nal, Pya, Phe (X), Phg (X), wherein X is optional single the replacement or two replacements of hydrogen, halogen, nitro, carboxyl or C1-C4 alkyl, and substituting group is selected from H, 4-F, 3-F, 2-F, 4-Cl, 2-Cl, 4-Br, 2-Br, 3-Br, 2,5-2Cl, 4-F, 3-Cl, 3-NO 2
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, the amino process PEG modification in site arbitrarily in the compound in wherein above-mentioned (I) group, become the compound shown in following (II) group, wherein said amino comprises the amino and amino acid side chain amino of N-end:
[PEG-X-(CH 2) MCO-NH] Z-X 1-Y 1-Y 2-X 2
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 3
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 3-X 4
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
[PEG-X-(CH 2) MCO-NH] Z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7(II)
Wherein PEG represents: RO (CH 2CH 2O) n-CH 2CH 2, R=H or C and CH 3, n=5-1000 wherein; X=O, NH or NHCO; M=0-6; Z=1-3, X 1, X 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4Definition as noted above.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, wherein the carboxyl in any site of (I) group compound is the compound that (III) as follows organizes through the PEG covalent modification, wherein said carboxyl comprises C-end carboxyl, aspartic acid and L-glutamic acid side chain carboxyl group:
[PEG-X-CO] z-X 1-Y 1-Y 2-X 2
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 3
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 3-X 4
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
[PEG-X-CO] z-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
[PEG-X-CO] z-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
[PEG-X-CO] z-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
[PEG-X-CO] z-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
[PEG-X-CO] z-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7(III)
X wherein 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4State as defined above shown in, X=O or NH, Z=1-3.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, wherein in optional position in the peptide sequence shown in (I) group compound, comprise in N end and C end and the peptide fragment and introduce halfcystine, form the compound of (IV) group as follows:
Cys-X 1-Y 1-Y 2-X 2
Cys-X 1-X 2-Y 1-Y 2-X 3
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4
Cys-X 1-X 2-Y 1-Y 2-X 3-X 4
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7 (IV)
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, it is further modified the back with compound of described (IV) group through the method that is selected from PEG-MAL, PEG-VS and PEG-IODS and forms the compound that (V) as follows organizes, and wherein PEG can be chain, starlike, ring-type, multi-arm type structure:
PEG-M-Cys-X 1-Y 1-Y 2-X 2
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 3
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 3-X 4
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
PEG-M-Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
PEG-M-Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
PEG-M-Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
PEG-M-Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
PEG-M-Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7(V)，
Wherein
Figure G04196459220041207D000071
Cys is a halfcystine, links to each other with M group covalency by the side chain sulphur atom; X 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4State as defined above.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, wherein introduce Electron Affinities group or nucleophilic group at the C end of the compound of described (I) group, and it is corresponding to opposite nucleophilic group or the Electron Affinities group of N end introducing, obtain the compound of (VI) group as follows, wherein said nucleophilic reagent is selected from the iodine negative ion, water, the hydroxyl negative ion, the methoxyl group negative ion, the ethanoyl negative ion, amino, the nitrate radical negative ion, the nitrite anions negative ion, the azido-negative ion, the cyano group negative ion, 1-proyl negative ion, the dimethyl malonate negative ion, the sulfydryl negative ion, the methylthio group negative ion, the thiocyanogen negative ion, dimethyl sulphide, front three phosphorus; Described electrophilic reagent is selected from thiocarboxyl group acetyl ammonia, halogen, mineral acid, organic acid, aldehyde, active ketone, carboxylic acid, ester, nitro-compound:
Z 1-X 1-Y 1-Y 2-X 2-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 3-Z 2
Z 1-X 1-X 2-X 3-Y 1-Y 2-X 4-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 3-X 4-Z 2
Z 1-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4-Z 2
Z 1-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4-Z 2
Z 1-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5-Z 2
Z 1-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6-Z 2
Z 1-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7-Z 2
Z 1-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7-Z 2 (VI)，
Z wherein 1And Z 2Be one group of amino-acid residue or other fragment, work as Z with nucleophilic group and Electron Affinities group 1Z when having nucleophilic group 2Have the Electron Affinities group, work as Z 1Z when having the Electron Affinities group 2Have nucleophilic group.
Preferably, above-mentioned tetrapeptide to ten peptide derivant and steric isomer thereof, it is:
CEVVE-SCH 2CH 2CONH 2
CKEVVE-SCH 2CH 2CONH 2
CKKEVVE-SCH 2CH 2CONH 2
CKEVVEE-SCH 2CH 2CONH 2
CEKKEVVE-SCH 2CH 2CONH 2
CKEKKEVVE-SCH 2CH 2CONH 2
CKEVVEKEVVE-SCH 2CH 2CONH 2
CKEVVEEAE-SCH 2CH 2CONH 2
CKEVVEEA-SCH 2CH 2CONH 2, or
CKEVVEEAEN-SCH 2CH 2CONH 2。
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, wherein (IV) and (VI) any site of the compound of group introduce aliphatic chain, aliphatic ether chain, thioether chain, amino acid and other flexible chain-like structure unit, obtain the compound of (VII) group as follows:
Cys-L n-X 1-Y 1-Y 2-X 2
Cys-L n-X 1-X 2-Y 1-Y 2-X 3
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4
Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5
Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3
Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6
Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4
Cys-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5
Cys-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6
Cys-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7
Cys-L n-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7
Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7，
Or following structure:
Z 1-L n-X 1-Y 1-Y 2-X 2-Z 2
Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-Z 2
Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-Z 2
Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Z 2
Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Z 2
Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-Z 2
Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4-Z 2
Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4-Z 2
Z 1-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5-Z 2
Z 1-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6-Z 2
Z 1-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7-Z 2
Z 1-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7-Z 2
Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7-Z 2?(VII)
Wherein, L represents the chain-like structure unit of any flexibility, n=1-4, the site, L place shown in the above general formula is not the unique site that can introduce, L can be in peptide sequence the optional position except that two ends.
Preferably, tetrapeptide to ten peptide derivant of the present invention and steric isomer thereof, it comprises:
CLEVVE
CLKEVVE
CLKKEVVE
CLKEVVEE
CLEKKEVVE
CLKEKKEVVE
CLKEVVEKEVVE
CLKEVVEEAE
CLKEVVEEA
CLKEVVEEAEN
CLLEVVE
CLLKEVVE
CLLKKEVVE
CLLKEVVEE
CLLEKKEVVE
CLLKEKKEVVE
CLLKEVVEKEVVE
CLLKEVVEEAE
CLLKEVVEEA
CLLKEVVEEAEN，
Or the compound of following structure:
CLEVVE-SCH 2CH 2CONH 2
CLKEVVE-SCH 2CH 2CONH 2
CLKKEVVE-SCH 2CH 2CONH 2
CLKEVVEE-SCH 2CH 2CONH 2
CLEKKEVVE-SCH 2CH 2CONH 2
CLKEKKEVVE-SCH 2CH 2CONH 2
CLKEVVEKEVVE-SCH 2CH 2CONH 2
CLKEVVEEAE-SCH 2CH 2CONH 2
CLKEVVEEA-SCH 2CH 2CONH 2
CLKEVVEEAEN-SCH 2CH 2CONH 2
CLLEVVE-SCH 2CH 2CONH 2
CLLKEVVE-SCH 2CH 2CONH 2
CLLKKEVVE-SCH 2CH 2CONH 2
CLLKEVVEE-SCH 2CH 2CONH 2
CLLEKKEVVE-SCH 2CH 2CONH 2
CLLKEKKEVVE-SCH 2CH 2CONH 2
CLLKEVVEKEVVE-SCH 2CH 2CONH 2
CLLKEVVEEAE-SCH 2CH 2CONH 2
CLLKEVVEEA-SCH 2CH 2CONH 2
CLLKEVVEEAEN-SCH 2CH 2CONH 2, wherein, L=
-NHCH 2CH 2OCH 2COO-。
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, wherein the compound with arbitrary aforementioned (I), (IV), (VII) group carries out cyclization with any known cyclization method, obtains the ring compound shown in (VIII) group:
Ring (X 1-Y 1-Y 2-X 2)
Ring (X 1-X 2-Y 1-Y 2-X 3)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4)
Ring (X 1-X 2-Y 1-Y 2-X 3-X 4)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
Ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
Ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
Ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
Ring (X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
Ring (X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
Ring (X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
Ring (X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Or following structure:
Ring (Cys-X 1-Y 1-Y 2-X 2)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 3)
Ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4)
Ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
Ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
Ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
Ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
Ring (Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
Ring (Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
Ring (Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
Ring (Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Or following compound:
Ring (Z 1-L n-X 1-Y 1-Y 2-X 2)
Ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3)
Ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4)
Ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4)
Ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
Ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
Ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
Ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
Ring (Z 1-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
Ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
Ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
Ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7) (VIII)
Wherein, X 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4State as defined above shown in, Z 1State as defined above shown in, L nState as defined above shown in.
Preferably, tetrapeptide to ten peptide derivant of the present invention and steric isomer thereof, it is following structure:
Ring (EVVE)
Ring (KEVVE)
Ring (KKEVVE)
Ring (KEVVEE)
Ring (EKKEVVE)
Ring (KEKKEVVE)
Ring (KEVVEKEVVE)
Ring (KEVVEEAE)
Ring (KEVVEEA)
Ring (KEVVEEAEN)
Or
Ring (CEVVE)
Ring (CKEVVE)
Ring (CKKEVVE)
Ring (CKEVVEE)
Ring (CEKKEVVE)
Ring (CKEKKEVVE)
Ring (CKEVVEKEVVE)
Ring (CKEVVEEAE)
Ring (CKEVVEEA)
Ring (CKEVVEEAEN)
Or:
Ring (CLEVVE)
Ring (CLKEVVE)
Ring (CLKKEVVE)
Ring (CLKEVVEE)
Ring (CLEKKEVVE)
Ring (CLKEKKEVVE)
Ring (CLKEVVEKEVVE)
Ring (CLKEVVEEAE)
Ring (CLKEVVEEA)
Ring (CLKEVVEEAEN)
Or:
Ring (CLLEVVE)
Ring (CLLKEVVE)
Ring (CLLKKEVVE)
Ring (CLLKEVVEE)
Ring (CLLEKKEVVE)
Ring (CLLKEKKEVVE)
Ring (CLLKEVVEKEVVE)
Ring (CLLKEVVEEAE)
Ring (CLLKEVVEEA)
Ring (CLLKEVVEEAEN).
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, the amino in any site is modified through PEG in the compound of wherein said (VIII) group, obtain the compound of (XI) as follows group, wherein said amino comprises the side chain amino of N-end amino and natural amino acid or alpha-non-natural amino acid
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-Y 1-Y 2-X 2)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-Y 1-Y 2-X 2)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Or:
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-Y 1-Y 2-X 2)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
[PEG-X-(CH 2) MCO-NH] Z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7) (XI),
Wherein said PEG represents: RO (CH 2CH 2O) n-CH 2CH 2, R=H or C and CH 3, n=5-1000; X=O, NH or NHCO; M=0-6; Z=1-3, X 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4State as defined above shown in, Z 1, L nState as defined above shown in.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, comprises following compound:
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVEE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVEKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVEEAE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVEEA)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CKEVVEEAEN)
Or following structure:
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVEE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVEKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVEEAE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVEEA)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLKEVVEEAEN)
Or the compound of following structure:
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVEE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEKKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVEKEVVE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVEEAE)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVEEA)
PEG-CH 2CH 2-X-(CH 2) mCO-encircles (CLLKEVVEEAEN)
Wherein, X=O, NH or NHCO; M=0-6.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, the wherein carboxyl process PEG modification in site arbitrarily in the compound of (VIII) group, obtain the compound shown in following (IX), wherein said amino comprises the side chain carboxyl group of C-end amino and natural amino acid or alpha-non-natural amino acid:
[PEG-X-CO] z-ring (X 1-Y 1-Y 2-X 2)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-CO] z-ring (X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-CO] z-ring (X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-CO] z-ring (X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-CO] z-ring (X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
[PEG-X-CO] z-ring (X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7)
[PEG-X-CO] z-ring (Cys-X 1-Y 1-Y 2-X 2)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-CO] z-ring (Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-CO] z-ring (Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Or following structure:
[PEG-X-CO] z-ring (Z 1-L n-X 1-Y 1-Y 2-X 2)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
[PEG-X-CO] z-ring (Z 1-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
[PEG-X-CO] z-ring (Z 1-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y3-Y4-X 7) (IX)
Wherein, X 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4Definition shown in claim 1, Z 1, L nState as defined above shown in; X=O or NH, Z=1-3.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, is selected from:
[PEG-X-CO] z-ring (EVVE)
[PEG-X-CO] zRing (KEVVE)
[PEG-X-CO] zRing (KKEVVE)
[PEG-X-CO] zRing (KEVVEE)
[PEG-X-CO] zRing (EKKEVVE)
[PEG-X-CO] zRing (KEKKEVVE)
[PEG-X-CO] zRing (KEVVEKEVVE)
[PEG-X-CO] zRing (KEVVEEAE)
[PEG-X-CO] zRing (KEVVEEA)
[PEG-X-CO] zRing (KEVVEEAEN)
[PEG-X-CO] z-ring (CEVVE)
[PEG-X-CO] zRing (CKEVVE)
[PEG-X-CO] zRing (CKKEVVE)
[PEG-X-CO] zRing (CKEVVEE)
[PEG-X-CO] zRing (CEKKEVVE)
[PEG-X-CO] zRing (CKEKKEVVE)
[PEG-X-CO] zRing (CKEVVEKEVVE)
[PEG-X-CO] zRing (CKEVVEEAE)
[PEG-X-CO] zRing (CKEVVEEA)
[PEG-X-CO] zRing (CKEVVEEAEN)
Or following structure:
[PEG-X-CO] zRing (CLEVVE)
[PEG-X-CO] zRing (CLKEVVE)
[PEG-X-CO] zRing (CLKKEVVE)
[PEG-X-CO] zRing (CLKEVVEE)
[PEG-X-CO] zRing (CLEKKEVVE)
[PEG-X-CO] zRing (CLKEKKEVVE)
[PEG-X-CO] zRing (CLKEVVEKEVVE)
[PEG-X-CO] zRing (CLKEVVEEAE)
[PEG-X-CO] zRing (CLKEVVEEA)
[PEG-X-CO] zRing (CLKEVVEEAEN)
Or the compound of following structure:
[PEG-X-CO] zRing (CLLEVVE)
[PEG-X-CO] zRing (CLLKEVVE)
[PEG-X-CO] zRing (CLLKKEVVE)
[PEG-X-CO] zRing (CLLKEVVEE)
[PEG-X-CO] zRing (CLLEKKEVVE)
[PEG-X-CO] zRing (CLLKEKKEVVE)
[PEG-X-CO] zRing (CLLKEVVEKEVVE)
[PEG-X-CO] zRing (CLLKEVVEEAE)
[PEG-X-CO] zRing (CLLKEVVEEA)
[PEG-X-CO] zRing (CLLKEVVEEAEN).
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, after wherein halfcystine is introduced in compound optional position in peptide sequence or existing halfcystine position or sequence of (VIII) group, through being selected from PEG-MAL, the method of PEG-VS and PEG-IODS is modified, obtain the compound of (X) as follows group, wherein PEG can be chain, starlike, ring-type, multi-arm type structure:
PEG-M-encircles (Cys-X 1-Y 1-Y 2-X 2)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 3)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
PEG-M-encircles (Cys-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
PEG-M-encircles (Cys-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6)
PEG-M-encircles (Cys-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
PEG-M-encircles (Cys-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
Also can be following structure:
PEG-M-encircles (Cys-L n-X 1-Y 1-Y 2-X 2)
PEG-M-encircles (Cys-L n-X 1-X 2-Y 1-Y 2-X 3)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4)
PEG-M-encircles (Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5)
PEG-M-encircles (Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3)
PEG-M-encircles (Cys-L n-X 1-X 2-Y 1-Y 2-X 3-X 4-Y 3-X 5-Y 4)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-Y 3-X 6-Y 4)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-X 4-X 5-X 6-Y 1-Y 2-X 7)
PEG-M-encircles (Cys-X 1-X 2-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-Y 1-Y 2-X 4-X 5-X 6-Y 3-Y 4-X 7)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-X 4-Y 1-Y 2-X 5)
PEG-M-encircles (Cys-L n-X 1-X 2-X 3-X 4-X 5-Y 1-Y 2-X 6) (X)
Wherein,
X wherein 1, Z 1Can be halfcystine, link to each other with M group covalency by the side chain sulphur atom; X 1, X 2, Y 1, Y 2, X 3, X 4, X 5, X 6, X 7, Y 1, Y 2, Y 3, Y 4State as defined above shown in, Z 1, L nState as defined above shown in.
Another aspect of the present invention relates to tetrapeptide to ten an as described below peptide derivant and steric isomer thereof, and it is selected from:
[PEG-M]-ring (CEVVE)
[PEG-M]-ring (CKEVVE)
[PEG-M]-ring (CKKEVVE)
[PEG-M]-ring (CKEVVEE)
[PEG-M]-ring (CEKKEVVE)
[PEG-M]-ring (CKEKKEVVE)
[PEG-M] encircles (CKEVVEKEVVE)
[PEG-M] encircles (CKEVVEEAE)
[PEG-M]-ring (CKEVVEEA)
[PEG-M]-ring (CKEVVEEAEN)
Or following structure:
[PEG-M]-ring (CLEVVE)
[PEG-M]-ring (CLKEVVE)
[PEG-M]-ring (CLKKEVVE)
[PEG-M]-ring (CLKEVVEE)
[PEG-M]-ring (CLEKKEVVE)
[PEG-M]-ring (CLKEKKEVVE)
[PEG-M]-ring (CLKEVVEKEVVE)
[PEG-M]-ring (CLKEVVEEAE)
[PEG-M]-ring (CLKEVVEEA)
[PEG-M]-ring (CLKEVVEEAEN)
Or the compound of following structure:
[PEG-M]-ring (CLLEVVE)
[PEG-M]-ring (CLLKEVVE)
[PEG-M]-ring (CLLKKEVVE)
[PEG-M]-ring (CLLKEVVEE)
[PEG-M] encircles (CLLEKKEVVE)
[PEG-M]-ring (CLLKEKKEVVE)
[PEG-M]-ring (CLLKEVVEKEVVE)
[PEG-M]-ring (CLLKEVVEEAE)
[PEG-M]-ring (CLLKEVVEEA)
[PEG-M]-ring (CLLKEVVEEAEN).
The invention still further relates at least a be selected from above-mentioned (I), (II), (III),, the compound of (IV), (V), (VI), (VII), (VIII), (IX), (X) group or its arbitrary be combined in that preparation is used for the treatment of and/or the medicine of epidemic prevention defective or hypoimmunity diseases related in purposes.
The invention still further relates to pharmaceutical composition, comprising at least a compound that is selected from above-mentioned (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) group, and pharmaceutical carrier or vehicle.
The invention still further relates to preparation above-mentioned (I), (II), (III),, the method for the compound of (IV), (V), (VI), (VII), (VIII), (IX), (X) group, it comprises with known solution method and solid phase method and synthesizing.
The used PEG-OH structure of the present invention is: RO (CH 2CH 2O) NCH 2CH 2OH, wherein R=H or CH 3, molecular-weight average can be used as commercialization reagent by the PEG-OH of hundreds of to several ten thousand and buys PEG-NH 2, PEG-NHCOCH 2CH 2COOH can obtain by following approach reaction:
Figure G04196459220041207D000251
Concrete, the amino acid in that the end elder generation of PEG introduces amino, carboxyl or preparation PEGization is coupled in the peptide sequence with solution method or solid-phase synthesis and goes, can realize the N-end amino to polypeptide, C-holds carboxyl, Lys side chain amino, the modification of Asp or Glu side chain carboxyl group is with PEG-NH 2With maleic anhydride, vinyl sulfoxide, iodo acetic anhydride can obtain PEG-MAL, PEG-VS, PEG-IODO.
Wang Resin involved in the present invention, MBHA Resin, DCC, HOBt, HBTU, BOP, Fmoc amino acid, BOC protect amino acid, and reagent such as TFA, DIEA, m PEG-OH, NMM all obtain by buying.All alpha-non-natural amino acids are synthetic and fractionation by this laboratory.
According to the present invention, have with immune deficiency or immunologic hypofunction diseases associated: hepatitis B, hepatitis C, nonsmall-cell lung cancer, melanoma, acquired immune deficiency syndrome (AIDS) etc.
According to the present invention, used term such as T α 1 (17-27) refer to the sequence of holding C-end corresponding position in T α 1 from N-.
The T α 1 active fragments derivative and the steric isomer thereof of (I)-(X) shown in the present group or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be enteron aisle or non-enteron aisle, as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritonaeum or rectum etc.
Form of administration is tablet, capsule, dripping pill, aerosol, pill, pulvis, solution, suspensoid, emulsion, granule, liposome, transdermal agent, buccal tablet, suppository, lyophilized injectable powder etc. for example.Can be ordinary preparation, sustained release preparation, controlled release preparation and various particulate delivery system.
For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.About the example of carrier, comprise for example thinner and absorption agent, as starch, dextrin, lactose, N.F,USP MANNITOL, sucrose, glucose, calcium sulfate, sodium-chlor, urea, lime carbonate, white bole, Microcrystalline Cellulose, pure aluminium silicate etc.; Wetting agent and tackiness agent are as water, glycerine, polyoxyethylene glycol, ethanol, propyl alcohol, starch slurry, dextrin, syrup, honey, glucose solution, mucialga of arabic gummy, gelatine size, Xylo-Mucine, lac, methylcellulose gum, potassiumphosphate, polyvinylpyrrolidone etc.; Disintegrating agent is as dry starch, alginates, agar powder, laminaran, sodium bicarbonate and Citric Acid, lime carbonate, polyoxyethylene sorbitol fatty acid ester, sodium laurylsulfonate, methylcellulose gum, ethyl cellulose etc.; The disintegration inhibitor is as sucrose, Tristearoylglycerol, theobroma oil, hydrogenation wet goods; Absorption enhancer is as quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant is as talcum powder, silicon-dioxide, W-Gum, stearate, boric acid, whiteruss, polyoxyethylene glycol etc.Tablet further can also be made coating tablet, as sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablets and multilayer tablet.For pill is made in the administration unit, can be extensive use of various carrier well known in the art.Example about carrier is, for example thinner and absorption agent are as glucose, lactose, starch, theobroma oil, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talcum powder etc.; Tackiness agent such as gum arabic, tragacanth gum, gelatin, ethanol, honey, rice paste or batter etc.; Disintegrating agent is as agar powder, dry starch, alginates, sodium laurylsulfonate, methylcellulose gum, ethyl cellulose etc.For suppository is made in the administration unit, can be extensive use of various carrier well known in the art.Example about carrier is, for example the ester of polyoxyethylene glycol, Yelkin TTS, theobroma oil, higher alcohols, higher alcohols, gelatin, semi-synthetic glyceryl ester etc.For capsule is made in the administration unit, effective constituent formula (I)-(X) T α 1 active fragments derivative or its steric isomer are mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard capsule or soft capsule.Also tripeptide derivative or its steric isomer of effective constituent (I)-(X) group can be made microcapsule, be suspended in and make suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.For injection preparation is made in the administration unit, as solution, emulsion, lyophilized injectable powder and suspensoid, can use this area all thinners commonly used, as water, ethanol, polyoxyethylene glycol, 1, the isooctadecanol of the isooctadecanol of ammediol, ethoxylation, polyoxy baseization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection liquid, can in injection preparation, add proper amount of sodium chloride, glucose or glycerine, in addition, can also add conventional solubility promoter, buffer reagent, pH regulator agent etc. in order to prepare etc.
In addition, as needs, also can in pharmaceutical preparation, add tinting material, sanitas, spices, correctives, sweeting agent or other material.
The compound of the present invention (I)-(X) group, the dosage of derivative or its steric isomer depends on many factors, for example to prevent or treat the character and the severity of the T α 1 active fragments derivative disease of (I)-(X) group, the sex of patient or animal, age, body weight and individual reaction, used particular compound, route of administration and administration number of times etc.Above-mentioned dosage can the single dose form or be divided into several, for example two, in, four dosage form administrations.
The abbreviation of Shi Yonging in the present invention has following implication:
Ac ethanoyl HOBt I-hydroxybenzotriazole
Ala (A) L-Ala HOSu N-hydroxy-succinamide
Alloc allyloxycarbonyl IL interleukin-
Allyl allyl group IFN Interferon, rabbit
Asn (N) N X (? )-S-CH 2CH 2CONH 2
Asp (D) aspartic acid Lys (K) Methionin
Boc tertbutyloxycarbonyl NK natural killer
Bzl benzyl OD optical density(OD)
PMeOBzl to methoxy-benzyl Y (? )-NHCH 2CH 2OCH 2COO-
TBU tertbutyloxycarbonyl MPEG mono methoxy polyethylene glycol
ConA canavaline Val (V) Xie Ansuan
CY ring phosphinylidyne ammonia P (Ph 3) triphenyl phosphorus
Cys (C) halfcystine HF hydrogen fluoride
DCM methylene dichloride Ts-Cl Tosyl chloride
DMF N, the reverse high performance liquid chromatography of dinethylformamide RP-HPLC
TFA trifluoracetic acid TEA triethylamine
EDT dithioglycol TLC thin-layer chromatography
DIEA diisopropylethylamine mPEG-MAL mono methoxy polyethylene glycol horse
BOP benzotriazole-1-oxygen-three (two Glu (E) L-glutamic acid
Fmoc fluorenylmethyloxycarbonyl DCC dicyclohexylcarbodiimide
The experiment of ESI-MS electrospray ionization mass spectrum ELISA enzyme linked immunological
MALDI-TOF-MS is substance assistant laser desorpted
The ionization flight time mass spectrum
Among the present invention, all amino acid configurations are the L-type except that being labeled as the D-type.
Embodiment
The following example is represented illustrative embodiment of the present invention, but does not mean that the present invention is subjected to the restriction of this embodiment.
The used solid-phase synthesized carrier Wang resin of embodiment is buied from ACT company, and DCC, HOBt, HBTU, Fmoc protection amino acid is buied by Shanghai gill biochemistry, and TFA is an ACROS company product, and molecular-weight average is that 2000 PEG-OH is a Sigma company product.
Embodiment 1
BocNHCH 2CH 2OCH 2COOH's is synthetic:
Figure G04196459220041207D000281
● BocNHCH 2CH 2OH's is synthetic
Water 30ml is added in the 250ml reactor NH 2CH 2CH 2OH6.1g (100mmol) adds in the reactor, is cooled to 0 ℃.Under condition of ice bath, (Boc) 2O21.82g (100mmol) is dissolved in the 30ml dioxane and joins in the reactor, and controlled temperature drips 1mol/LnaOH solution 100ml below 0 ℃, and 40min drips, and rises to room temperature naturally, continues reaction 12 hours, (Boc) 2O disappears, stopped reaction, and the some plate detects, and reaction solution ethyl acetate extraction three times with saturated NaCl solution washing, are used anhydrous Na 2The SO4 drying, evaporated under reduced pressure obtains the 15.6g colorless oil, yield 97.2%.
● BocNHCH 2CH 2OCH 2COOH's is synthetic
In the 500ml there-necked flask, add and heavily steam DMF350ml, BocNH 2CH 2OH10.54g (0.1mol) adds NaH (52%) 8.15g (0.2mol), and no bubble is emerged to the solution, drips BrCH then 2The DMF solution of COOH13.65g (0.15mmol), stirring at room 20 hours is handled, pressure reducing and steaming DMF, with the suitable quantity of water dissolving, with an amount of extracted with diethyl ether twice, water is regulated the pH value between 2-3 with saturated sodium sulfate, with ethyl acetate extraction water three times, use saturated NaCl solution washing then, use anhydrous sodium sulfate drying at last, evaporated under reduced pressure, obtain the 5.51g light yellow oil, yield 38%.
Embodiment 2:
Cys-Glu-Val-Val-Glu-SCH 2CH 2CONH 2Synthetic:
(charge capacity is 0.57mmol/g to the 350mgMBHA resin, 0.2mmol), be suspended among the DMF, add 0.12gHOBt successively, 150 μ L 3-thiohydracrylic acids (1.2mmol), 160mg DCC, add a spot of DCM dissolving fully, at room temperature magnetic agitation was 4 hours, with DMF, DCM, each washed twice of MeOH, DCM, each two minutes.The triketohydrindene hydrate check is negative.Use 50mg acthiol-J hydrochloride (0.2mmol) then; 100mg (0.2mmol) triphenyl phosphorus and 120 μ lDIEA (0.2mmol) mixing are dissolved in DMF; add in the resin after five minutes; room temperature reaction two hours; use DMF; DCM; MeOH; each twice of DCM washing; the amino acid of the BOC protection of 4 times of amounts; BOP; the DIEA of 6 times of amounts mixes; be dissolved in DMF; mixture joins in the reactor after five minutes; room temperature reaction 2 hours; with DMF; DCM; MeOH; the DCM washing; detect with Ellman experiment qualitatively; negative solution resin is colourless or faint yellow; reacted one hour if be orange then reduce by half with above-mentioned condensation dosage again; use BOC/Bzl solid phase condensation system and progressively prolong peptide chain from the C end; with 4NHCl/DIOX (0.05% indoles) deprotection; condensation reaction was reacted 1 hour with the BOC-AA of 2 times of amounts and the DCC/HOBt of 2 times of amounts; per step condensation all detects with the triketohydrindene hydrate experiment; if it is positive then use the BOC-AA of 4 times of amounts again; the DIEA reaction half hour of BOP and 6 times of amounts; after the peptide chain end of synthesis; linear peptides thioesters HF/P-thiocresol/m-cresol (93/2/5; v/v/v); downcut from resin after 1.5 hours 0 ℃ of reaction; HF drains the back and washs for several times with the freezing anhydrous diethyl ether of sodium silk exsiccant; Glacial acetic acid with 10% extracts thick peptide, and freeze-drying is preserved.
Embodiment three: encircle the synthetic of (CEVVE):
(charge capacity is 0.57mmol/g to the 350mgMBHA resin, 0.2mmol), be suspended among the DMF, add 0.12gHOBt successively, 150 μ L 3-thiohydracrylic acids (1.2mmol), 160mg DCC, add a spot of DCM dissolving fully, at room temperature magnetic agitation was 4 hours, with DMF, DCM, each washed twice of MeOH, DCM, each two minutes.The triketohydrindene hydrate check is negative.Use 50mg acthiol-J hydrochloride (0.2mmol) then; 100mg (0.2mmol) triphenyl phosphorus and 120 μ lDIEA (0.2mmol) mixing are dissolved in DMF; add in the resin after five minutes; room temperature reaction two hours; use DMF; DCM; MeOH; each twice of DCM washing; the amino acid of the BOC protection of 4 times of amounts; BOP; the DIEA of 6 times of amounts mixes; be dissolved in DMF; mixture joins in the reactor after five minutes; room temperature reaction 2 hours; with DMF; DCM; MeOH; the DCM washing; detect with Ellman experiment qualitatively; negative solution resin is colourless or faint yellow; reacted one hour if be orange then reduce by half with above-mentioned condensation dosage again; use BOC/BZL solid phase condensation system and progressively prolong peptide chain from the C end; with 4NHCl/DIOX (0.05% indoles) deprotection; condensation reaction was reacted 1 hour with the BOC-AA of 2 times of amounts and the DCC/HOBt of 2 times of amounts; per step condensation all detects with the triketohydrindene hydrate experiment; if it is positive then use the BOC-AA of 4 times of amounts again; the DIEA reaction half hour of BOP and 6 times of amounts; after the peptide chain end of synthesis; linear peptides thioesters HF/P-thiocresol/m-cresol (93/2/5; v/v/v); downcut from resin after 1.5 hours 0 ℃ of reaction; HF drains the back and washs for several times with the freezing anhydrous diethyl ether of sodium silk exsiccant; Glacial acetic acid with 10% extracts thick peptide, and freeze-drying is preserved.Also the buffered soln of cyclization directly can be extracted the linear peptides thioesters and carry out ring-closure reaction.If peptide thioesters solubleness is bad, it is also conceivable that and use CH 3CN/H 2O extracts thick peptide, and CH is taken out in decompression then 3Freeze-drying is preserved behind the CN.
The linear peptides thioesters carries out ring-closure reaction after with gel filtration chromatography preliminary purification or HPLC purifying, be reflected at NaHCO 3The aqueous solution in carry out, can suitably add CH if solubleness is bad 3The concentration of CN, control pH value adds the oxidation that TCEP prevents sulfydryl at 7.3-7.6, and reaction is reflected in 4 hours and is finished by the HPLC monitoring, and product is identified with ESI-MS.
Embodiment four: (CKEVVEE's is synthetic for the PEG-MAL-ring
1mPEG 5000-MAL's is synthetic
Weighing m PEG 5000-OH 20g (4mmol) places the 250ml reaction flask, adds 100mlCH 2Cl 2, add 3.0ml Et again after the solid dissolving 3N (20mmmol) and 3.8gTs-Cl (20mmol), the stirring at room reaction.TLC (CH 3OH: CH 2Cl 2=1: 6) monitoring reaction fully after, rotary evaporation removes and desolvates, and adds the 100ml anhydrous diethyl ether and is settled out solid, uses dehydrated alcohol recrystallization twice again, 15.2g mPEG 5000-OTs, yield 70%.
With 15g mPEG 5000-OTs (3mmol) is dissolved in 30ml DMF, adds 1.68g (18mmol) potassium phthalimide, at N 2Under the protection, 120 ℃ were reacted 4 hours.The pressure reducing and steaming solvent is dissolved in the 50ml dehydrated alcohol with resistates, adds the 2.0ml hydrazine hydrate, back flow reaction 4 hours.Rotary evaporation removes and desolvates, and resistates is dissolved in CH 2Cl 2, remove by filter insolubles, the filtrate rotary evaporation is removed desolvate again, be settled out solid with anhydrous diethyl ether, again with dehydrated alcohol-ether recrystallization, get 12.5g mPEG 5000-NH 2, yield 83%.
With 1.25g mPEG 5000-NH 2Be dissolved in the 10ml dioxane, add maleic anhydride 0.1g, 80 ℃ of stirring reaction 30min.The pressure reducing and steaming solvent adds the 50ml anhydrous diethyl ether, and cooling is settled out solid, and filter collection solid gets 1.10g after the drying.The gained solid is dissolved in the 15ml diacetyl oxide, adds the 0.5g sodium acetate, 100 ℃ of stirring reaction 45min.The pressure reducing and steaming solvent dissolves resistates with methylene dichloride, the elimination insolubles adds proper amount of active carbon in filtrate, place 30min, the filtering gac is concentrated into filtrate dried, add anhydrous diethyl ether, be settled out solid, get light yellow solid 0.61g mPEG after filter collection, the drying 5000-MAL, yield 48%.RP-HPLC analyzes: t R=36.79min.
Chromatographic condition: Waters 600 HPLC
Chromatographic column: Inersil ODS-3 (10 * 250mm) ultraviolet detection wavelength: 215nm
Moving phase: A-0.05%TFA/H 2O B-0.05%TFA/70%CH 3CN/H 2O
Flow velocity: 2.0mL/min
Gradient (linearity): t (min) A% B%
0 100 0
5 100 0
35 0 100
40 0 100
45 100 0
(charge capacity is 0.57mmol/g to the 350mgMBHA resin, 0.2mmol), be suspended among the DMF, add 0.12gHOBt successively, 150 μ L 3-thiohydracrylic acids (1.2mmol), 160mg DCC, add a spot of DCM dissolving fully, at room temperature magnetic agitation was 4 hours, with DMF, DCM, each washed twice of MeOH, DCM, each two minutes.The triketohydrindene hydrate check is negative.Use 50mg acthiol-J hydrochloride (0.2mmol) then; 100mg (0.2mmol) triphenyl phosphorus and 120 μ lDIEA (0.2mmol) mixing are dissolved in DMF; add in the resin after five minutes; room temperature reaction two hours; use DMF; DCM; MeOH; each twice of DCM washing; the amino acid of the BOC protection of 4 times of amounts; BOP; the DIEA of 6 times of amounts mixes; be dissolved in DMF; mixture joins in the reactor after five minutes; room temperature reaction 2 hours; with DMF; DCM; MeOH; the DCM washing; detect with Ellman experiment qualitatively; negative solution resin is colourless or faint yellow; reacted one hour if be orange then reduce by half with above-mentioned condensation dosage again; use BOC/Bzl solid phase condensation system and progressively prolong peptide chain from the C end; with 4NHCl/DIOX (0.05% indoles) deprotection; condensation reaction was reacted 1 hour with the BOC-AA of 2 times of amounts and the DCC/HOBt of 2 times of amounts; per step condensation all detects with the triketohydrindene hydrate experiment; if it is positive then use the BOC-AA of 4 times of amounts again; the DIEA reaction half hour of BOP and 6 times of amounts; after the peptide chain end of synthesis; linear peptides thioesters HF/P-thiocresol/m-cresol (93/2/5; v/v/v); downcut from resin after 1.5 hours 0 ℃ of reaction; HF drains the back and washs for several times with the freezing anhydrous diethyl ether of sodium silk exsiccant; Glacial acetic acid with 10% extracts thick peptide, and freeze-drying is preserved.
2, ring (CEVVE) is synthetic:
(charge capacity is 0.57mmol/g to the 350mgMBHA resin, 0.2mmol), be suspended among the DMF, add 0.12gHOBt successively, 150 μ L 3-thiohydracrylic acids (1.2mmol), 160mg DCC, add a spot of DCM dissolving fully, at room temperature magnetic agitation was 4 hours, with DMF, DCM, each washed twice of MeOH, DCM, each two minutes.The triketohydrindene hydrate check is negative.Use 50mg acthiol-J hydrochloride (0.2mmol) then; 100mg (0.2mmol) triphenyl phosphorus and 120 μ lDIEA (0.2mmol) mixing are dissolved in DMF; add in the resin after five minutes; room temperature reaction two hours; use DMF; DCM; MeOH; each twice of DCM washing; the amino acid of the BOC protection of 4 times of amounts; BOP; the DIEA of 6 times of amounts mixes; be dissolved in DMF; mixture joins in the reactor after five minutes; room temperature reaction 2 hours; with DMF; DCM; MeOH; the DCM washing; detect with Ellman experiment qualitatively; negative solution resin is colourless or faint yellow; reacted one hour if be orange then reduce by half with above-mentioned condensation dosage again; use BOC/BZL solid phase condensation system and progressively prolong peptide chain from the C end; with 4NHCl/DIOX (0.05% indoles) deprotection; condensation reaction was reacted 1 hour with the BOC-AA of 2 times of amounts and the DCC/HOBt of 2 times of amounts; per step condensation all detects with the triketohydrindene hydrate experiment; if it is positive then use the BOC-AA of 4 times of amounts again; the DIEA reaction half hour of BOP and 6 times of amounts; after the peptide chain end of synthesis; linear peptides thioesters HF/P-thiocresol/m-cresol (93/2/5; v/v/v); downcut from resin after 1.5 hours 0 ℃ of reaction; HF drains the back and washs for several times with the freezing anhydrous diethyl ether of sodium silk exsiccant; Glacial acetic acid with 10% extracts thick peptide, and freeze-drying is preserved.Also the buffered soln of cyclization directly can be extracted the linear peptides thioesters and carry out ring-closure reaction.If peptide thioesters solubleness is bad, it is also conceivable that and use CH 3CN/H 2O extracts thick peptide, and CH is taken out in decompression then 3Freeze-drying is preserved behind the CN.
The linear peptides thioesters carries out ring-closure reaction after with gel filtration chromatography preliminary purification or HPLC purifying, be reflected at NaHCO 3The aqueous solution in carry out, can suitably add CH if solubleness is bad 3The concentration of CN, control pH value adds the oxidation that TCEP prevents sulfydryl at 7.3-7.6, and reaction is reflected in 4 hours and is finished by the HPLC monitoring, and product is identified with ESI-MS.
3, the PEG-MAL of cyclic peptide modifies
Will be soluble in water through the ring behind the RP-HPLC purifying (CEVVE), transfer pH to 8 with sodium bicarbonate, add 3 times of normal mPEG 5000-MAL, room temperature reaction, with RP-HPLC monitoring reaction process and separated product, reaction was generally finished in four hours.
Cys (mPEG 5000-MAL)-T α 1(17-24) analyze through MALDI-TOF-MS, a series of peaks are arranged near 6173, it is about 44 that adjacent two peak molecular weight differ, and has the typical structure feature of polyoxyethylene glycol.By with the mPEG-NH that does not connect the cyclic peptide molecule 2Relatively, deduct the formula weight as the maleoyl imido of activation functional group, the molecular weight of its value fundamental sum cyclic peptide is corresponding, proves the mPEGization modification that has successfully realized the cyclic peptide compound.
Embodiment 5: 3The H-tdR method of mixing detects the increment reaction to mouse spleen lymphocyte:
The preparation of splenocyte suspension: aseptic taking-up spleen, with frosted glass plate mouse spleen is ground, make splenocyte suspension.After the splitting erythrocyte, wash three times counting (viable cell is more than 95%).With the RPMI1640 nutrient solution that contains 10%FBS splenocyte concentration is adjusted to 4 * 10 6Cell/ml.This experiment adds ConA (concanavalin A) 5ug/ml inducer T lymphocyte propagation.With 3H-TdR mixes the propagation that standard measure is measured cell.At 37 ℃, 5%CO 2Cultivated 48 hours in the incubator.Before finish cultivating 7-8 hour, every hole added 25 μ l 3The H-thymidylic acid (contains 2 * 10 4Bq).After cultivate finishing, with the cell harvesting instrument (HARVESTER, TOMTEC) collecting cell on glass fibre membrane, with liquid dodge the numeration instrument (MicroBeta Trilux, PerkinElmer) detect [ 3H]-incorporation of thymidine in DNA, represent the cell proliferation situation with the cpm value.Concrete detected result is referring to table 1.
Result evaluation: proliferation of lymphocytes adopts detected sample cpm value to deduct positive control sample cpm value, removes positive control sample cpm value then, be labeled as+strengthen/-% of inhibition.In view of specimen does not have the non-specific cytotoxicity effect, result queue is+(enhancing)/-more than 15% of (inhibition) (common during more than 10% also can) according to the P value, just represent that sample has activity.
Table 1T α 1And the T lymphproliferation response result of analogue
Measure concentration The T lymphocyte T cell proliferation Active result
The sample name Con A stimulates Comprehensive activity assessment
ug/ml CPM mean value SD The P value
Contrast ?28659 420
CKEVVEKEVVE 1 ?25205 1864 0.0784 -12.05％
10 ?28512 524 0.7245 -0.05％
100 ?41342 2942 0.0159 44.26％
CKEVVEEA 1 ?29405 2950 0.7055 2.60％
10 ?30715 2841 0.3362 7.17％
100 ?61281 2531 0.0016 113.83％
Ring (CKEVVEEAE) 1 ?27561 1113 0.2233 -3.83％
10 ?32792 424 0.0003 14.42％
100 ?61476 122 0.0000 114.51％
Ring (CKEVVE) 1 ?28143 1633 0.6434 -1.80％
10 ?34065 1427 0.0162 18.86％
100 ?61766 5163 0.0077 115.52％
Ring (CEVVE) 1 ?30065 2055 0.3576 4.90％
10 ?33462 3431 0.1342 16.76％
100 ?58669 1059 0.0001 104.71％
Ring (CKEVVEEA) 1 ?27000 2980 0.4371 -5.79％
10 ?32206 2111 0.0954 12.38％
100 ?53927 5412 0.0145 88.17％
Ring (CLKEVVE) 1 ?21205 897 0.0013 -26.01％
10 ?47060 529 0.0000 64.21％
100 ?57103 1733 0.0007 99.25％
Ring (CKEVVEKEVVE) 1 ?27461 831 0.1135 -4.18％
10 ?31907 967 0.0164 11.33％
100 ?44826 1871 0.0031 56.41％
Ring (CKEVVEE) 1 ?29557 1574 0.4293 3.13％
10 ?34137 737 0.0012 19.11％
100 ?37684 1990 0.0129 31.49％
The cpm value is represented the cell proliferation situation, and SD is the standard deviation of data, and this carries out the probability that indifference is arranged of statistical study P value representation experimental data and ConA control group data, between P＜two groups of data of 0.05 expression significant difference is arranged.L＝-NHCH 2CH 2OCH 2COOH-

Claims (5)

1. be selected from following peptide derivant and steric isomer thereof:
CEVVE-SCH 2CH 2CONH 2
CKEVVEKEVVE-SCH 2CH 2CONH 2Or
CKEVVEEA-SCH 2CH 2CONH 2。
2. peptide derivant and steric isomer thereof, it comprises:
CLEVVE-SCH 2CH 2CONH 2
CLKEVVE-SCH 2CH 2CONH 2
CLKEVVEKEVVE-SCH 2CH 2CONH 2
CLKEVVEEA-SCH 2CH 2CONH 2
CLLEVVE-SCH 2CH 2CONH 2
CLLKEVVE-SCH 2CH 2CONH 2
CLLKEVVEKEVVE-SCH 2CH 2CONH 2
CLLKEVVEEA-SCH 2CH 2CONH 2
Wherein, L=-NHCH 2CH 2OCH 2COO-.
3. peptide derivant and steric isomer thereof, it is the compound of following structure:
Ring (CEVVE).
4. be selected from arbitrary compound of each described peptide derivant of claim 1～3 and steric isomer thereof and the purposes that arbitrary combination is used to prepare the medicine that treats and/or prevents immune deficiency, immunologic hypofunction relative disease thereof.
5. be selected from arbitrary compound of each described peptide derivant of claim 1～3 and steric isomer thereof and the purposes that arbitrary combination is used to prepare healthcare products and makeup thereof.
CN2004100964592A 2004-12-01 2004-12-01 Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative Expired - Fee Related CN1781933B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2004100964592A CN1781933B (en) 2004-12-01 2004-12-01 Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative
CN201110034234.4A CN102174084B (en) 2004-12-01 2004-12-01 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2004100964592A CN1781933B (en) 2004-12-01 2004-12-01 Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210241191.1A Division CN102746385B (en) 2004-12-01 2004-12-01 Thymosin alpha 1 active fragment cyclopeptide analogue and polyethylene glycol derivative thereof
CN201110034234.4A Division CN102174084B (en) 2004-12-01 2004-12-01 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Publications (2)

Publication Number Publication Date
CN1781933A CN1781933A (en) 2006-06-07
CN1781933B true CN1781933B (en) 2011-07-20

Family

ID=36772597

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110034234.4A Expired - Fee Related CN102174084B (en) 2004-12-01 2004-12-01 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof
CN2004100964592A Expired - Fee Related CN1781933B (en) 2004-12-01 2004-12-01 Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201110034234.4A Expired - Fee Related CN102174084B (en) 2004-12-01 2004-12-01 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Country Status (1)

Country Link
CN (2) CN102174084B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174084B (en) * 2004-12-01 2015-11-18 中国人民解放军军事医学科学院毒物药物研究所 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746385B (en) * 2004-12-01 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 Thymosin alpha 1 active fragment cyclopeptide analogue and polyethylene glycol derivative thereof
CN1927879B (en) * 2006-09-25 2010-11-24 吉林大学 Thymopentapeptide active isomer and application thereof in pharmaceutical preparation
EP2168602A4 (en) * 2007-06-12 2014-10-29 Inst Pharm & Toxicology Amms Site-specific pegylated linear salmon calcitonin derivatives
CN102796168B (en) * 2011-05-27 2014-02-26 首都医科大学 Compounds with thrombolytic activity and preparation method and application thereof
CN107428800B (en) * 2015-07-08 2020-11-27 中国食品发酵工业研究院 Active peptide for inhibiting AMPA receptor and preparation method and application thereof
CN114173791A (en) * 2019-07-17 2022-03-11 波兹皮埃德公司 Boron-containing RHO kinase inhibitors
CN111454329A (en) * 2020-04-07 2020-07-28 哈尔滨师范大学 Isoindolinone bridged cyclic nonapeptide with anticancer activity and preparation method thereof
CN112315909B (en) * 2020-11-05 2023-02-17 南开大学 Functional polymer micelle PM-TLK and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3100974A1 (en) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Medicaments having immunoregulating action which contain thymosin alpha 1 fragments, and thymosin alpha 1 fragments
CN1990037B (en) * 2003-03-21 2011-08-10 中国人民解放军军事医学科学院毒物药物研究所 Thymosin alpha1 active fragment and polyethylene glycol derivative thereof
CN102174084B (en) * 2004-12-01 2015-11-18 中国人民解放军军事医学科学院毒物药物研究所 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Thomas L. Ciardelli, Genevieve S. Incefy, and Christian Birr.Activity of synthetic thymosin .alpha.1 C-terminalpeptidesintheazathioprine E-rosette inhibition assay.Biochemistry21 18.1982,21(18),4234-4236.
Thomas L. Ciardelli, Genevieve S. Incefy, and Christian Birr.Activity of synthetic thymosin .alpha.1 C-terminalpeptidesintheazathioprine E-rosette inhibition assay.Biochemistry21 18.1982,21(18),4234-4236. *
蒋志龙，郄建坤，刘克良.生物活性环肽研究进展.中国药物化学杂志14 2.2004,14(2),124-125.
蒋志龙,郄建坤,刘克良.生物活性环肽研究进展.中国药物化学杂志14 2.2004,14(2),124-125. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174084B (en) * 2004-12-01 2015-11-18 中国人民解放军军事医学科学院毒物药物研究所 Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof

Also Published As

Publication number Publication date
CN102174084B (en) 2015-11-18
CN1781933A (en) 2006-06-07
CN102174084A (en) 2011-09-07

Similar Documents

Publication Publication Date Title
JP3266311B2 (en) Novel polypeptide and anti-HIV agent using the same
FI77875B (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA PEPTIDER.
KR100225679B1 (en) Nonapeptide bombesin antagonists
CN1781933B (en) Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative
RU2073685C1 (en) Polypeptides or their salts, pharmaceutical composition showing antiviral activity with respect to human immunodeficiency virus
CN104231067B (en) Erythropoietin mimetic peptide chemical dimer and application thereof
CA2020838C (en) Hemoregulatory peptides
WO2017008661A1 (en) Polypeptide compound and preparation method and use thereof
WO2016206597A1 (en) Polypeptide compound and preparation method and use thereof
US20240131111A1 (en) Composition of bl-8040
KR20180086277A (en) POLYPEPTIDE COMPOUNDS AND METHODS AND PROCESSES FOR THEIR PREPARATION
US11993631B2 (en) Process for manufacturing peptide
CN102746385B (en) Thymosin alpha 1 active fragment cyclopeptide analogue and polyethylene glycol derivative thereof
CN103965297A (en) Polypeptide as well as preparation method and application thereof
CN101265292B (en) Polypeptides substances, preparing method and use thereof
CN1990037B (en) Thymosin alpha1 active fragment and polyethylene glycol derivative thereof
CN103012555A (en) Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment
CN115974978A (en) Polypeptide anti-tumor active compound, pharmaceutical composition and application in preparation of anti-tumor drugs
KONOPIŃSKA et al. Influence of the peptide chain length of new elongated tuftsin analogs on phagocytosis process
CN114989259A (en) Small molecular peptide Ped4 and application thereof
CN1168143A (en) Antitumor agents isolated from intestinal mucosa, method for their isolation and their application
CN116621943A (en) Long-acting hepatitis virus entry inhibitor
CN116621944A (en) Long-acting hepatitis virus entry inhibitor
CN103044524A (en) Preparation method of new polypeptide, and application of new polypeptide in treatment
JPH03170498A (en) Peptide and drug having interleukin-1 like activity and containing the peptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110720

Termination date: 20151201

EXPY Termination of patent right or utility model